Table 2.
Papers directly comparing PsA and psoriasis patients using or not using SGCs in RCTs
| Study |
Baseline characteristics |
Treatment and assessment of psoriatic flare or morphological shift description |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1st author (year) | Publication type | Aim of study | Dx | n | Age (Y, range) | SGC [dose, RoA] | Treatment duration | Co-medication | Reason for initiation of SGC | Skin flare or morphological shift during or after tapering of SGC | Percentage of flares |
| Carubbi 2016 | RCT | Comparing efficacy and safety between SGC and TNF IA treatment | PsA | 41 | 42.95 (31–68) | Triamcinolone (40 mg/month, IA), SGC (NOS) | 3 months | Stable dose of anti-TNF in combination with one or more DMARDS | Refractory arthritis | No adverse events were reported during the 52-wk follow-up | 0% |
| Gupta 2007 | Open-label-RCT | Comparing efficacy and safety of MTX + betamethasone or MTX only | Psoriasis | 40 |
|
betamethasone [3 mg/wk, PO] | Until complete clearance of lesions: 27.13 days (24.74–29.52) | 15 mg MTX PO | Psoriasis | No flares after discontinuation (91.78 days in remission) | 0% |
Dx: diagnosis; Y: year; RoA: route of administration; RCT: randomized controlled trial; SGC: systemic glucocorticoid; NOS: not otherwise specified; PO; oral.